Related Experiment Video
Updated: Apr 28, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Immunotherapy for non-small-cell lung cancer
Anish Thomas1, Marko Jakopovic
1National Cancer Institute, National Institutes of Health, Center for Cancer Research, Thoracic and GI Oncology Branch , Building 10-CRC/4-5330, Bethesda, MD 20892 , USA.
Activating the immune system is a promising cancer treatment. For non-small-cell lung cancer (NSCLC), checkpoint inhibitors show potential by overcoming tumor immune evasion, unlike less effective vaccines and stimulants.
Area of Science:
- Oncology
- Immunology
Background:
- Immunotherapy is a key strategy for treating cancers, including non-small-cell lung cancer (NSCLC).
- Various immunotherapies like immune stimulants, vaccines, and checkpoint inhibitors have been investigated in clinical trials for NSCLC.
Discussion:
- Nonspecific immune stimulants and vaccines have generally failed to show significant clinical benefit in large Phase III trials for NSCLC.
- Checkpoint inhibitors target immune checkpoints, a critical mechanism tumors use to evade the immune system, by blocking inhibitory signals within the tumor microenvironment.
Key Insights:
- Checkpoint inhibitors have demonstrated promising early clinical results, including durable responses in some NSCLC patients.
- Understanding NSCLC-specific immunosuppression mechanisms is vital for identifying patients likely to benefit from immunotherapy.
Outlook:
- Further evaluation of vaccine efficacy in specific patient subsets is warranted.
- Tailoring immunotherapy selection based on a deeper understanding of tumor immunology will be crucial for improving treatment outcomes in NSCLC.
More Related Videos
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...